From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs
Abstract Reversing or slowing the aging process brings great promise to treat or prevent age‐related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for interve...
Saved in:
| Main Authors: | Rebecca L McIntyre, Eileen G Daniels, Marte Molenaars, Riekelt H Houtkooper, Georges E Janssens |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-08-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201809854 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Longevity cosmeceuticals as the next frontier in cosmetic innovation: a scientific framework for substantiating product claims
by: Wannita Klinngam, et al.
Published: (2025-05-01) -
The role of HDAC6 in fibrosis: a novel and effective therapy strategy
by: Liangliang Zheng, et al.
Published: (2025-07-01) -
dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation
by: Mohammad Mijanur Rahman, et al.
Published: (2024-12-01) -
HDAC10 and its implications in Sézary syndrome pathogenesis
by: Monika Pieniawska, et al.
Published: (2025-01-01) -
Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer
by: Shannon E. Lynch, et al.
Published: (2025-03-01)